Novo Nordisk Skids After Cutting Its Outlook For The Third Time This YearInvestors Business Daily • 11/05/25
Novo Nordisk's obesity pill shows cardiovascular benefits, comparable efficacy to injectionReuters • 11/05/25
Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for MetseraMarket Watch • 11/05/25
Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiationsReuters • 11/05/25
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mountCNBC • 11/05/25
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continuesGlobeNewsWire • 11/05/25
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns ItBenzinga • 11/04/25
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To ClimbBenzinga • 11/04/25
Lilly and Novo Nordisk near White House deal on obesity drug prices, Endpoints New reportsReuters • 11/04/25
Metsera said it received a revised acquisition offer from Novo Nordisk that it called superior to Pfizer's bidWSJ • 11/04/25
Metsera says Novo Nordisk's new bid for obesity drugmaker is ‘superior' to revised Pfizer offerCNBC • 11/04/25